Theratechnologies Inc. (THTX) |
|
1.35 -0.76 (-36.02%)
|
12-02 16:00 |
|
Open: |
1.31 |
Pre. Close: |
2.11 |
|
High:
|
1.49 |
Low:
|
1.26 |
|
Volume:
|
1,354,506 |
Market Cap:
|
128(M) |
|
|
|
Technical analysis |
as of: 2022-12-02 4:26:37 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 2.21  One year: 2.67 |
| Support: |
Support1: 1.25 Support2: 1.04 |
| Resistance: |
Resistance1: 1.89 Resistance2: 2.28 |
| Pivot: |
2.03 |
| Moving Average: |
MA(5): 1.96 MA(20): 2
MA(100): 2.11 MA(250): 2.44 |
| MACD: |
MACD(12,26): -0.1 Signal(9): 0 |
| Stochastic oscillator: |
%K(14,3): 47.8 %D(3): 62.7 |
| RSI: |
RSI(14): 26.3 |
| 52-week: |
High: 3.36 Low: 1.25 |
| Average Vol(K): |
3-Month: 266 (K) 10-Days: 153 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ THTX ] has closed below the lower bollinger band by 29.3%. Bollinger Bands are 159.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 7 days. This is a sign that the current trend might continue. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
1.49 - 1.5 |
1.5 - 1.51 |
|
Low:
|
1.24 - 1.25 |
1.25 - 1.26 |
|
Close:
|
1.33 - 1.35 |
1.35 - 1.37 |
|
Company Description |
|
Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; TH1902, which is in Phase 1/Part A clinical trials for the treatment of triple negative breast cancer; and TH1904 for the treatment of ovarian cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada. |
Headline News |
Fri, 02 Dec 2022
U.S. stocks mixed at close of trade; Dow Jones Industrial Average up 0.10% By Investing.com - Investing.com
Fri, 02 Dec 2022
Health Care Sector Update for 12/02/2022: THTX, TH.TO, PGNY, RDHL, AVXL - Nasdaq
Fri, 02 Dec 2022
Healthcare Stocks Moving Friday: SHPH, RMED, AVXL, DMAC, THTX, VAXX, KTRA, ENSC - InvestorsObserver
Fri, 02 Dec 2022
Rigel going toe-to-toe with Servier in r/r AML with Rezlidhia nod - BioWorld Online
Wed, 30 Nov 2022
Jonestrading Initiates Coverage on Theratechnologies (NASDAQ:THTX) - MarketBeat
Fri, 18 Nov 2022
Cantor Fitzgerald has begun research coverage of Theratechnologies (NASDAQ:THTX). - Best Stocks
|
Financial Analysis |
| Price to Book Value: |
Underperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Outperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Underperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
95 (M) |
|
% Held by Insiders
|
8.576e+007 (%) |
|
% Held by Institutions
|
1.2 (%) |
|
Shares Short
|
74 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-2.262e+007 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
-63.6 |
|
Operating Margin (%)
|
-46.5 |
|
Return on Assets (ttm)
|
-20.2 |
|
Return on Equity (ttm)
|
-1 |
|
Qtrly Rev. Growth
|
7.739e+007 |
|
Gross Profit (p.s.)
|
12.11 |
|
Sales Per Share
|
85.29 |
|
EBITDA (p.s.)
|
3.75547e+007 |
|
Qtrly Earnings Growth
|
-0.4 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-12 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
0.01 |
|
Price to Cash Flow
|
-9.74 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
87950 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
